Clinical Trial Update: A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study [Phase 3]

View source ↗

Summary

This update presents long-term follow-up data from participants who previously received delandistrogene moxeparvovec (SRP-9001) in a Duchenne muscular dystrophy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Delandistrogene moxeparvovec (delandistrogene moxeparvovec)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: ENROLLING_BY_INVITATION